Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis.

Makoto Kashimura, Yuki Fujioka, Yong-Mei Guo, Teruko Takahashi, Keiichi Moriya, Naoto Takahashi

Abstract readCase Reports

In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Makoto KashimuraDivision of Hematology, Shinmatsudo Central General Hospital, Matsudo, Japan.

Yuki FujiokaDivision of Central Laboratory, Akita University Hospital, Akita, Japan.

Yong-Mei GuoDivision of Hematology, Shinmatsudo Central General Hospital, Matsudo, Japan.

Teruko TakahashiDivision of Hematology, Shinmatsudo Central General Hospital, Matsudo, Japan.

Keiichi MoriyaDivision of Hematology, Shinmatsudo Central General Hospital, Matsudo, Japan.

Naoto TakahashiDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan. naotot@doc.med.akita-u.ac.jp.ORCID http://orcid.org/0000-0002-6758-3787

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Achieving treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) requires several years of tyrosine kinase inhibitor (TKI) therapy and a sustained deep molecular response (DMR). We report an exceptional case of a 54-year-old woman who achieved long-term TFR despite discontinuing dasatinib after only 9 months due to grade 3 interstitial pneumonitis. At the time of discontinuation, the duration of DMR was 128 days. Following cessation, BCR::ABL1 transcript levels transiently rebounded to 0.0729% on the International Scale but subsequently declined spontaneously without resumption of TKI therapy. The patient has remained in TFR for more than 7 years. Immunological analysis revealed clonal expansion of a unique CD56

Indexed as

DasatinibLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLung Diseases, InterstitialProtein Kinase InhibitorsFemaleFusion Proteins, bcr-ablHumansMiddle AgedRemission InductionTime FactorsTreatment InterruptionDasatinibFusion Proteins, bcr-ablProtein Kinase InhibitorsChronic myeloid leukemiaDasatinibImmune surveillanceNK-like T-cellTreatment-free remission

Identifiers

PMID42377752

DOI10.1007/s12185-026-04241-y

PMCPMC13407438

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.